Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2014 | special report | Ausgabe 3/2014

memo - Magazine of European Medical Oncology 3/2014

Long-term tolerability of the BRAF inhibitor vemurafenib in patients with metastatic melanoma: current study data and real-life observations

memo - Magazine of European Medical Oncology > Ausgabe 3/2014
MD Cathrin Balmelli, MD Michael Mark, MD Christian Spirig, MD Vito Spataro, MD Stefanie Pederiva, MD Christian Monnerat, Prof. Alfred Zippelius, MD, PhD Andreas Wicki


Vemurafenib is a targeted therapy against metastatic melanoma. It specifically inhibits the V600 mutated BRAF kinase in the mitogen-activated protein kinase pathway. Only limited data are available on long-term tolerability and efficacy of this drug. Here, we report and discuss six patients from our own clinical practice who were treated with vemurafenib for 16–27 months. Overall, these long-term responders tolerated vemurafenib well during the prolonged period of therapy. Most of the side-effects occurred during the first 6 months of treatment and were transient. The most common persistent side-effect was phototoxicity, which was manageable by precautionary measures or with dose reduction. Interestingly, even permanent dose reductions of 50 % of the standard dose did not abrogate long lasting remissions but improved tolerability, which is a prerequisite of long-term therapy. In addition to our own clinical experience, this article reviews current study results regarding the tolerability and efficacy of long-term vemurafenib therapy.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 3/2014

memo - Magazine of European Medical Oncology 3/2014 Zur Ausgabe